MedTrace Logo

MT10109L in the Treatment of Lateral Canthal Lines

NCT03785145 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 235

Last updated 2023-10-05

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and efficacy of MT10109L in the treatment of lateral canthal lines (LCL) in participants with moderate to severe LCL.

Conditions

  • Lateral Canthal Lines

Interventions

DRUG

MT10109L

MT10109L will be injected into the LCL.

DRUG

Placebo

Placebo will be injected into the LCL.

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Principal Investigators

  • SangMi Park · Medytox Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-20
Primary Completion
2020-02-27
Completion
2021-01-25
FDA Drug
Yes

Countries

  • United States
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03785145 on ClinicalTrials.gov